• Flagship launch of Clinico-branded Audeara healthy hearing earbuds into Taiwan
• All payments received for $2.1m contract with global music instrument manufacturer Avedis Zildjian
• Launch of Audeara Buds - Audeara's first in-ear product to capture the growing True Wireless audio market

Audeara Ltd (ASX: AUA) has provided an update on its Q2 FY25 activities, highlighting several key achievements and progress across its business. The company successfully launched its Clinico-branded Audeara healthy hearing earbuds in Taiwan, following a $0.57m purchase order in October 2024. Audeara also received all payments related to its $2.1m contract with global music instrument manufacturer Avedis Zildjian, resulting in the successful launch of Zildjian's Alchem-E product line. Additionally, the company launched the Audeara Buds, its first in-ear product designed to capture the growing True Wireless audio market. Audeara continued to engage with key industry stakeholders, attending the European Union of Hearing Aid Acousticians (EUHA) Congress in Germany and being recognized as a finalist in the 2024 Australian Export Awards. The company also showcased its products at CES 2025 with partner Eastech Ltd. Audeara further strengthened its position by extending its supply contract with the world's largest audiology retailer for an additional two years. Financially, the company reported Q2 FY25 cash receipts of $1.13m, up 70% year-over-year, and YTD revenue of $2.45m, up 211% on the prior comparative period.

Audeara expects to continue its strong growth trajectory, with the successful launch of the Audeara Buds and Clinico-branded earbuds expected to contribute to the company's revenues in the coming quarters.

Audeara remains focused on driving operational efficiencies and capturing new sales and distribution opportunities across its core domestic and emerging international markets. The company is well-positioned to execute on its strategic vision and unlock further value in the years ahead.